Pharmaceutical Plastic Packaging Market (2026 - 2036)

Pharmaceutical Plastic Packaging Market Forecast and Outlook 2026 to 2036

In 2025, the pharmaceutical plastic packaging market surpassed a valuation of USD 29.5 billion. Based on Fact.MR analysis, demand for pharmaceutical plastic packaging is estimated to grow to USD 30.9 billion in 2026 and USD 50.3 billion by 2036. Fact.MR projects a CAGR of 5.0% during the forecast period.

The market is expected to generate an absolute dollar opportunity of USD 20.8 billion between 2026 and 2036, a genuinely transformational expansion for an industry segment long characterized by incremental volume growth and commoditized resin pricing. Growth is driven structurally by two parallel forces: the rapid expansion of biologics and injectable therapies that demand complex, high-barrier, and contamination-free primary packaging, and tightening sustainability mandates across the EU and North America.

Dietmar Siemssen, CEO of Gerresheimer AG noted that, "The operative performance of our business in the first nine months is clearly below our expectations. Our goal is to grow faster than the overall market again in the medium and long term. The expansion of our product portfolio to include systems and solutions for biologics and the implementation of our growth projects will contribute considerably to this."

Country-level growth varies based on biologics investment, regulatory requirements, and healthcare infrastructure expansion. China leads with 7.0% CAGR, supported by pharmaceutical expansion under Made in China 2025 and rising biologics exports requiring certified primary packaging. India follows at 6.7%, driven by the Production Linked Incentive scheme boosting domestic drug manufacturing and demand for quality plastic packaging. The United States grows at 5.0%, supported by increasing novel drug approvals and investment in prefilled syringe and injectable manufacturing. Germany records 4.5% growth due to its strong EU-regulated manufacturing base, while the United Kingdom grows at 4.0%, supported by post-Brexit regulatory alignment and NHS supply chain investment.

Market Definition

The pharmaceutical plastic packaging market covers the design and production of plastic-based primary and secondary packaging used to protect and deliver pharmaceutical products. It includes bottles, vials, blister packs, pouches, prefillable syringes, closures, and films made from polyethylene, polypropylene, PET, and PVC. These formats ensure contamination control, barrier protection, and regulatory compliance across oral, liquid, injectable, and home healthcare applications.

Market Inclusions

This report provides global and regional revenue forecasts from 2026 to 2036 by material, end use, and region. It includes primary packaging, contract manufacturing formats, high-barrier substrates, rigid and flexible solutions, smart packaging integration, mono-material developments, and sustainable resin transitions across pharma and biotech sectors.

Market Exclusions

The scope excludes glass packaging, aluminium foil blisters, paper cartons, and finished drug products unless highlighting packaging trends. Consumer plastic packaging for food or cosmetics is excluded unless pharmaceutical-grade. Standalone fill-finish and contract packaging services are also excluded.

Research Methodology

• Primary Research: Interviews were conducted with pharmaceutical procurement managers, CDMO specialists, regulatory leaders, and resin suppliers across North America, Europe, and Asia Pacific.
• Desk Research: Sources included pharma annual reports, PPWR legislative records, FDA container closure guidance, pharmacopoeia standards, sustainability disclosures, and verified press releases.
• Market Sizing and Forecasting: A hybrid approach combined global drug output estimates with packaging unit consumption and pricing benchmarks. Inputs included biologics growth, regulatory-driven material shifts, and premium packaging trends.
• Data Validation and Update Cycle: Findings were validated using earnings disclosures, trade data, regulatory filings, and public M&A records. Forecasts are updated annually or after major regulatory or technology changes.

Pharmaceutical Plastic Packaging Market Summary

• Market Definition
  • Pharmaceutical plastic packaging includes polyethylene, polypropylene, PET, and PVC containers, blisters, syringes, and flexible formats used for compliant drug containment across global supply chains.
• Demand Drivers
  • Growth in biologics and injectables is increasing demand for high-value primary packaging such as prefillable syringes and advanced vials.
  • EU PPWR and FDA recyclability guidance are accelerating mono-material and sustainable packaging development, favoring established converters.
  • Manufacturing incentives in China and India are expanding generic and biosimilar production, boosting demand for certified plastic packaging.
• Key Segments Analyzed
  • By Material: Polyethylene holds around 38% share due to its dominance in oral solid dose bottles and cost-efficient barrier properties.
  • By End Use: Pharmaceuticals account for roughly 42% of demand, driven by steady procurement from branded and generic drug makers.
  • By Geography: Asia Pacific is the fastest-growing region, led by China at 7.0% CAGR and India at 6.7%, while Europe shows slower volume growth due to regulatory intensity.
• Analyst Opinion at FACT.MR
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, opines, 'Value in the pharmaceutical plastic packaging market is shifting decisively from commodity resin conversion to integrated smart and sustainable packaging systems. CXOs reviewing this report will find a market where regulatory compliance, biologics packaging complexity, and sustainability mandates are rewarding high-capability converters with premium margins while compressing returns for volume-only players.'
• Strategic Implications / Executive Takeaways
  • Manufacturers should accelerate mono-material and recycled-content substrate development with validated extractable profiles, as EU PPWR and FDA guidance will make sustainable formats a baseline requirement.
  • Asia Pacific converters should target China and India biologics and generics expansion through CDMO and state-backed pharma partnerships under government incentive schemes.
  • Global players should expand smart packaging capabilities such as RFID, NFC tracking, and temperature indicators to capture premium biologics and specialty drug segments.
• Methodology
  • Market size estimated using pharmaceutical production volumes, packaging consumption ratios, and material-specific pricing benchmarks validated through industry interviews.
  • Shares verified through company reports, trade association data, and official product announcements.
  • Regional forecasts based on biologics pipelines, manufacturing incentives, output growth, and sustainability regulation timelines.

Drivers, Restraints, and Opportunities

Fact.MR identifies the market as stable in volume but shifting in value. Pharmaceutical output growth ensures steady baseline demand, while biologics expansion and sustainability rules are redirecting value toward high-barrier and traceable packaging formats.

The market is dividing between commodity bottle suppliers and integrated system providers offering COP vials, prefillable syringes, and smart blister systems. Sustainable and smart formats carry higher unit costs but are increasingly preferred in regulated and high-risk drug categories, supporting overall price growth despite resin volatility.

• Biologics and Injectable Growth as Primary Structural Driver: Rapid expansion in monoclonal antibodies, biosimilars, and gene therapies is increasing demand for complex primary packaging. In May 2024, West Pharmaceutical Services launched Daikyo Crystal Zenith Nested Vials in Tub for biologics fill-finish applications.
• EU Packaging and Packaging Waste Regulation (PPWR) as Compliance Accelerator: The EU PPWR, effective from 2024 with phased implementation through 2030, mandates recyclability and recycled content thresholds. In January 2024, Alpek Polyester and TekniPlex Healthcare introduced a pharmaceutical-grade PET blister film with 30% recycled monomers to support compliance.
• Asia Pacific Manufacturing Scale and PLI-Driven Volume Expansion: Government-backed pharma expansion in China and India is driving new certified packaging demand. India’s PLI scheme continues through 2025.

Competitive Landscape for Market Players

The pharmaceutical plastic packaging market is moderately concentrated at the global system level but fragmented among regional commodity converters. Large players such as Amcor Berry, Gerresheimer, AptarGroup, and West Pharmaceutical Services hold strong positions due to pharmaceutical-grade certifications, long-standing customer relationships, proprietary materials, and integrated drug delivery capabilities. These companies focus on high-value segments including biologics packaging, injectable components, and sustainable formats where technical barriers are high.

Competitive advantage is increasingly tied to regulatory qualification rather than scale alone. For injectable and biologic drugs, packaging suppliers undergo multi-year validation processes, creating strong switching costs and protecting incumbent relationships. Gerresheimer’s 8.0 percent growth in its Plastics and Devices division in 2024 highlights the premium economics available in qualified system supply. Its acquisition of Bormioli Pharma further strengthens its integrated container and closure portfolio for biologics customers.

While generic drug packaging is often dual sourced and price sensitive, specialty and biologics packaging tends to rely on limited suppliers due to qualification complexity. Sustainability requirements are also becoming mandatory in procurement contracts, raising entry barriers and reinforcing the position of established, compliant players.

Recent Developments

• In April 2025, Amcor completed its all-stock acquisition of Berry Global for USD 8.4 billion, creating a combined packaging entity with approximately USD 23 billion in anticipated annual sales, approximately 70,000 employees, and operations across 140 countries with 400 production facilities, establishing the world's largest pharmaceutical and consumer packaging group.
• In December 2024, Gerresheimer completed its EUR 800 million acquisition of Blitz LuxCo Sarl, the holding company of Italy's Bormioli Pharma Group, which operates nine pharmaceutical primary packaging production sites in Europe specialising in glass and plastic bottles, closures, accessories, and dosing systems.

Scope of Report

Bibliography

• [1] West Pharmaceutical Services. (2024, May). West Pharmaceutical Services Launches Daikyo Crystal Zenith Nested Vials in Tub at ISCT 2024. PR Newswire.
• [2] TekniPlex Healthcare / Alpek Polyester. (2024, January). Alpek Polyester and TekniPlex Healthcare Launch Pharmaceutical-Grade PCR-PET Blister Film. Business Wire.
• [3] Berry Global. (2024, April). Berry Global Expands Healthcare Manufacturing Capacity in Three European Production Sites. Berry Global Corporate.
• [4] Amcor plc. (2025, April 30). Amcor Completes Combination with Berry Global. PR Newswire.
• [5] Berry Global. (2024, October). Berry Global Introduces ClariPPil Clarified Polypropylene Healthcare Bottles. Berry Global Corporate.
• [6] Gerresheimer AG. (2024, December 11). Gerresheimer Successfully Completes Acquisition of Blitz LuxCo Sarl, the Holding Company of the Bormioli Pharma Group. Gerresheimer Corporate.
• [7] Systech / Markem-Imaje. (2025, February). Systech Introduces UniSecure artAI AI-Powered Authentication System for Pharmaceutical Packaging. Globe Newswire.
• [8] Eli Lilly and Company. (2024, May). Eli Lilly Announces USD 5.3 Billion Manufacturing Expansion in Lebanon, Indiana. Eli Lilly Investor Relations.